CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative gene therapies for rare genetic diseases that affect the central nervous system (CNS), announced today that the Food and Drug Administration (FDA) has granted a Rare Pediatric Disease (RPD) designation for its gene therapy product candidate, AGIL-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.